MedTrace Logo

Utility of Mucosal Impedance Device in Chronic Esophageal Disorders:

NCT07227506 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2025-11-13

No results posted yet for this study

Summary

Background \& Significance Chronic benign esophageal disorders such as Gastroesophageal reflux disease (GERD) and eosinophilic esophagitis are common gastrointestinal disorders affecting nearly 20% and 0.1% of the population, respectively. Although these conditions are frequent, the diagnosis of GERD or EoE requires complex decision making involving endoscopic examination, histopathological examination, and esophageal pH testing. This translates into significant economic burden; For example, burden due to GERD is about $24 billion annually. Additionally, there may be a delay in the diagnosis of GERD or EoE as Investigators might have to do multiple procedures such as upper endoscopy, esophageal pH testing, etc for the same participant for confirmation of the diagnosis. In addition, there could be overlay between GERD and EoE in the diagnosis which make cause delay in the diagnosis and decision making.

Aim:

Here, Investigators will plan to identify the diagnostic utility and cost-effectiveness of this novel Mivu device(FDA approved) in the diagnosis of gastroesophageal reflux disease or chronic esophageal inflammatory disorders in participants with reflux symptoms or chronic esophageal symptoms.

Conditions

  • Gerd
  • Eosinophilic Esophagitis

Interventions

DEVICE

MuVI Esophageal mucosal impedance testing

Esophageal mucosal impedance values are checked in both groups

Sponsors & Collaborators

  • Medical College of Wisconsin

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-11-20
Primary Completion
2027-11-01
Completion
2028-07-01
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07227506 on ClinicalTrials.gov